Anamorelin Research

Matsukane R, Minami H, Fujimori N, Ueda K, Komori Y, Takamatsu Y et al.

Clinical evidence for anamorelin in pancreatic cancer is extremely limited, despite its approval in Japan. This study provides the first prospective evaluation of anamorelin specifically in pancreatic cancer, aiming to assess real-world efficacy and safety and to identify factors contributing to ...

Yamashita K, Nishio K, Mizutani S, Nishimura Y, Tarui M, Sakamoto S et al.

Patients undergoing curative surgery for upper gastrointestinal (UGI) cancers often experience substantial postoperative weight loss and reduction in muscle mass, one contributing factor being decreased ghrelin secretion following surgery. Anamorelin, a ghrelin receptor agonist, has been shown to...

Muscaritoli M, Molfino A, Orlando S, Tambaro F

Cancer cachexia is a multifactorial syndrome affecting up to 80% of advanced cancer patients, associated with poor quality of life, increased cancer-treatment toxicity, and reduced survival. Despite its clinical burden, no FDA- or EMA-approved pharmacologic therapies currently exist.This review c...

Akaishi H, Makiguchi T, Ishida Y, Shimanaka T, Tanaka H, Taima K et al.

Anamorelin has been approved for cancer cachexia in Japan. Anamorelin has been known to cause adverse events including QT prolongation and can lead to fatal arrhythmia. We report a first case of a male patient with non-small cell lung cancer who showed ST-T segment change following anamorelin. Fi...

Emori T, Itonaga M, Ashida R, Kitano M

Sarcopenia, characterized by loss of skeletal muscle mass and function, is a highly prevalent yet often overlooked condition in patients with gastrointestinal (GI) cancers. Emerging evidence suggests that sarcopenia is a significant predictor of poor prognosis across various stages of GI cancers....

Yamamoto K, Kurokawa Y, Miyazaki Y, Omori T, Yanagimoto Y, Shinno N et al.

Anamorelin, a ghrelin receptor agonist, has shown efficacy in lung cancer cachexia. We conducted the first randomized controlled trial to evaluate its effects in gastric cancer cachexia.In this multicenter, open-label randomized controlled trial conducted across 10 hospitals in Japan, patients wi...

Yoshida D, Ishimatsu M, Nakashima S, Nakano K, Ishida S, Orimoto H et al.

Cachexia is a multifactorial syndrome that adversely affects the prognosis of patients with gastrointestinal cancer. Although anamorelin has been shown to improve appetite and body weight, the optimal timing of its initiation remains unclear. This study evaluated the effects of the timing of anam...

Boku S, Yasuda T, Ikoma T, Matsumori E, Yoshiuchi S, Matsuo Y et al.

Anamorelin, a ghrelin receptor agonist, increases body weight and lean body mass (LBM); however, its effects on the gut microbiota remain unclear. Furthermore, the predictive value of nutritional scores, such as the Controlling Nutritional Status (CONUT) score, for anamorelin response is not esta...

Yamaguchi A, Kamada H, Semba S, Kato N, Teraoka Y, Mizumoto T et al.

Anamorelin, a ghrelin receptor agonist, has recently been used to treat cachexia in patients with pancreatic cancer (PC). Although it was accepted in Japan for advanced PC for the first time in the world in 2020, its efficacy and safety were not fully tested. Thus, we sought to determine the safe...

Yanagimoto Y, Yamashita K, Kawabata R, Omori T, Motoori M, Nakahara Y et al.

In 2021, anamorelin, a ghrelin receptor agonist, was approved in Japan for cancer cachexia in select cancers, including gastric cancer. However, evidence regarding its efficacy and predictive factors in patients with gastric cancer remains lacking.This prospective observational study encompassed ...

Odagiri K, Mimura Y, Naiki T, Tasaki Y, Sugiyama Y, Naiki-Ito A et al.

Cancer cachexia reduces chemotherapy efficacy in patients with metastatic urothelial carcinoma (mUC). Anamorelin improves cancer cachexia by increasing serum insulin-like growth factor 1 (IGF-1). The aim of this study was to evaluate the efficacy and safety of anamorelin in patients with mUC.A to...

Wang RL, Sun J, Liu H, Guo SM, Zhang Y, Hu W et al.

The growth hormone secretagogue receptor (GHSR) plays a critical role in regulating growth hormone release and metabolic homeostasis. Understanding the molecular mechanisms of ligand-GHSR recognition is essential for developing therapeutic interventions. In this study, we investigated the molecul...

von Haehling S, Langer HT, Heymsfield SB, Evans WJ, Anker SD

In December 2024, the Society on Cachexia and Wasting Disorders (SCWD) hosted a Regulatory and Trial Update Workshop in Washington, D.C., bringing together experts from academia, industry, and the US Food and Drug Administration (FDA). This article summarizes key topics discussed during the meeti...

Sasaya M, Takei D, Abe T, Hiraide M, Torigoe K, Nakayama T et al.

Real-world data on the effectiveness of anamorelin in managing cancer cachexia remains limited, particularly as its availability is currently restricted to Japan. In the present study, anamorelin use in cancer cachexia management was retrospectively evaluated, focusing on patient characteristics ...

Sumimoto T, Tanaka R, Sato A, Tatsuta R, Itoh H

Cancer cachexia is characterized by weight loss, muscle mass loss, and reduced food intake. Anamorelin is a ghrelin receptor agonist approved for the treatment of cancer cachexia. In this study, we established and validated an assay for quantification of anamorelin in human plasma.For quantificat...

Ogura M, Matsuoka H, Shinohara S, Umeki Y, Mastumoto N, Mizuno T et al.

Objective In 2021, anamorelin, an orally active ghrelin receptor selective antagonist, was approved for the treatment of cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colon cancer. Cancer cachexia is classified into three stages: pre-cachexia, cachex...

Maki M, Takada R, Ishigo T, Fujiwara M, Takahashi Y, Otsuka S et al.

Anamorelin (ANAM) is used to treat cancer-associated cachexia, a syndrome involving muscle loss and anorexia. The timing of the initiation of ANAM treatment is crucial to its efficacy. Although the body mass index (BMI) is a diagnostic criterion for cancer cachexia, no studies have explored its a...

Amano K, Naito T, Baracos VE

Fujii H, Yamada Y, Iihara H, Kobayashi R, Suzuki A

Cancer cachexia, a systemic multifactorial syndrome that affects survival prognosis, occurs in 80% of patients with advanced cancer. Patients with cancer cachexia experience progressive functional disability and persistent loss of skeletal muscle mass associated with reduced quality of life. Canc...

Okuro K, Hashimoto H, Morita K, Noshi Y, Kusushita M, Ochiai S et al.

Anamorelin is a selective ghrelin receptor agonist that is used to treat cancer-related cachexia. Ghrelin stimulates growth hormone (GH) secretion. However, the association between anamorelin and hyperglycemia remains unclear. We herein report a case of anamorelin induced hyperglycemia in a patie...